Pre-made Daratumumab benchmark antibody ( Whole mAb, anti-CD38 therapeutic antibody, Anti-ADPRC1/ADPRC 1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Daratumumab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Daratumumab, sold under the brand name Darzalex, is an anti-cancer medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-133-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Daratumumab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody
INN Name	Daratumumab
Target	CD38
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals
Conditions Approved	Multiple myeloma
Conditions Active	Amyloid light-chain amyloidosis;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor T-cell lymphoblastic leukaemia-lymphoma;Prostate cancer;T-cell lymphoma;Waldenstrom's macroglobulinaemia;Solid tumours
Conditions Discontinued	Non-small cell lung cancer
Development Tech	Medarex HuMAb Mouse